Treatments Dashboard

Treatments Dashboard

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatments Dashboard</th>
</tr>
<tr>
<td class="label">Metric</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Total Treatment Pages</td>
<td>538</td>
</tr>
<tr>
<td class="label">Alzheimer's Treatments</td>
<td>~120</td>
</tr>
<tr>
<td class="label">Parkinson's Treatments</td>
<td>~100</td>
</tr>
<tr>
<td class="label">ALS Treatments</td>
<td>~80</td>
</tr>
<tr>
<td class="label">Approved Therapies</td>
<td>~45</td>
</tr>
<tr>
<td class="label">Clinical Trial Candidates</td>
<td>~200</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Count</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>35</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>65</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>80</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Count</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>25</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>50</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>65</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Count</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>15</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>25</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>35</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class

Treatments Dashboard

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatments Dashboard</th>
</tr>
<tr>
<td class="label">Metric</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Total Treatment Pages</td>
<td>538</td>
</tr>
<tr>
<td class="label">Alzheimer's Treatments</td>
<td>~120</td>
</tr>
<tr>
<td class="label">Parkinson's Treatments</td>
<td>~100</td>
</tr>
<tr>
<td class="label">ALS Treatments</td>
<td>~80</td>
</tr>
<tr>
<td class="label">Approved Therapies</td>
<td>~45</td>
</tr>
<tr>
<td class="label">Clinical Trial Candidates</td>
<td>~200</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Count</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>35</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>65</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>80</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Count</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>25</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>50</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>65</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Count</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>15</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>25</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>35</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Leqembi</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">Kisunla</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Rytary</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Radicut</td>
<td>Mitsubishi</td>
</tr>
<tr>
<td class="label">Exserv</td>
<td>MT Pharma</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">[Cholinesterase Inhibitors](/entities/cholinesterase-inhibitors)</td>
<td>[Donepezil](/entities/donepezil), [Rivastigmine](/entities/rivastigmine)</td>
</tr>
<tr>
<td class="label">Dopamine Agonists</td>
<td>Pramipexole, Ropinirole</td>
</tr>
<tr>
<td class="label">MAO-B Inhibitors</td>
<td>Selegiline, Rasagiline</td>
</tr>
<tr>
<td class="label">NMDA Antagonists</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Active Trials</td>
</tr>
<tr>
<td class="label">Amyloid Clearance</td>
<td>45</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau) Propagation Blockers</td>
<td>38</td>
</tr>
<tr>
<td class="label">[Alpha-Synuclein](/proteins/alpha-synuclein) Aggregation</td>
<td>28</td>
</tr>
<tr>
<td class="label">LRRK2 Inhibition</td>
<td>22</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>42</td>
</tr>
<tr>
<td class="label">Metabolic Support</td>
<td>30</td>
</tr>
</table>

The Treatments Dashboard provides a comprehensive overview of therapeutic approaches and treatment coverage in NeuroWiki. This page serves as a central navigation hub for finding treatment information by disease, mechanism, and development stage. [@clinicaltrialsgov]

Quick Stats

Navigation

By Treatment Category

• [Treatments Overview](/therapeutics/overview) — Comprehensive treatment guide
• [Treatment Rankings](/therapeutics/rankings) — Ranked therapeutic approaches
• [Disease-Modifying Therapies](/therapeutics/disease-modifying-therapies) — DMT pipeline
• [Symptomatic Treatments](/therapeutics/symptomatic-treatments) — Symptom management

By Disease

• Alzheimer's Disease: [AD Therapeutic Scorecard](/therapeutics/ad-therapeutic-scorecard), [Anti-amyloid Therapies](/therapeutics/anti-amyloid-therapies), [Anti-tau Therapies](/therapeutics/anti-tau-therapies)
• Parkinson's Disease: [Dopamine Replacement](/therapeutics/dopamine-replacement-therapy), [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation), [AAV Gene Therapy](/therapeutics/aav-gene-therapy-neurodegeneration)
• ALS: [ALS Treatment Pipeline](/therapeutics/als-treatment-pipeline), [SOD1 Targeting](/therapeutics/sod1-targeting-therapies), [Anti-sense Oligonucleotides](/therapeutics/antisense-oligonucleotides-als)

By Mechanism

• [Amyloid Targeting](/therapeutics/amyloid-targeting)
• [Tau Targeting](/therapeutics/tau-targeting)
• [Alpha-Synuclein Targeting](/therapeutics/alpha-synuclein-targeting)
• [Neuroinflammation Modulation](/therapeutics/neuroinflammation-modulation)
• [Neuroprotection](/therapeutics/neuroprotection)

Treatment Pipeline Summary

Alzheimer's Disease Pipeline

Parkinson's Disease Pipeline

ALS Pipeline

Approved Therapies

Disease-Modifying Therapies (DMTs)

Symptomatic Treatments

Top Therapeutic Mechanisms

Research Focus Areas

Emerging Modalities

• [AAV Gene Therapy](/therapeutics/aav-gene-therapy-neurodegeneration) — Targeted delivery
• [PROTAC Technology](/therapeutics/proteolysis-targeting-chimeras) — Protein degradation
• [Anti-sense Oligonucleotides](/therapeutics/antisense-oligonucleotides) — Genetic targeting
• [Cell Replacement Therapy](/therapeutics/cell-replacement-therapy) — Regenerative approaches
• [Immunotherapy](/therapeutics/immunotherapy) — Antibody-based

Combination Therapy Approaches

• [AD Combination Therapy Matrix](/therapeutics/ad-combination-therapy-matrix)
• Multi-target approaches
• Sequential treatment strategies

Cross-Links

Related Sections

• [Biomarkers](/biomarkers) — Treatment response monitoring
• [Mechanisms](/mechanisms) — Mechanism of action
• [Clinical Trials](/clinical-trials) — Treatment trials
• [Investment](/investment) — Pharma pipeline analysis
• [Companies](/companies) — Treatment developers

External Resources

• [ClinicalTrials.gov](https://clinicaltrials.gov/)
• [Alzheimer's Association](https://www.alz.org/)
• [Parkinson's Foundation](https://www.parkinson.org/)
• [ALS Association](https://www.als.org/)

See Also

• [Treatments Overview](/mechanisms/dopaminergic-neuron-vulnerability)
• [Treatment Rankings](/therapeutics/rankings)
• [Disease](/therapeutics/disease-modifying-therapies-alzheimers)
• [Symptomatic Treatments](/therapeutics/parkinsons-symptomatic-treatments)
• [AD Therapeutic Scorecard](/mechanisms/dopaminergic-neuron-vulnerability)
• [Anti](/mechanisms/dopaminergic-neuron-vulnerability)
• [Anti](/mechanisms/dopaminergic-neuron-vulnerability)
• [Dopamine Replacement](/therapeutics/dopamine-replacement-therapy)
• [Deep Brain Stimulation](/technologies/deep-brain-stimulation)
• [AAV Gene Therapy](/investment/aav-gene-therapy)